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The distribution of carcinoembryonic antigen (CEA) in colorectal cancer (CRC) differs from that in normal colorectal tissue, being
found on all borders of the cell membrane and hence enabling access to intravenous antibody, making CEA a good target for
antibody-based therapy. The distinctive anti-CEA antibody, PR1A3, binds only membrane-bound CEA. Humanised PR1A3 (hPR1A3)
was assessed both in vitro cytotoxicity and binding assays with colorectal cancer cell lines expressing varying levels of CEA. Human
peripheral blood mononuclear cells (PBMCs) and purified natural killer (NK) cells were used as effectors. The in vitro assays
demonstrated hPR1A3 CEA-specific binding and antibody-dependent and CEA-specific killing of human colorectal cancer cell lines by
human PBMCs. The effect increased with increasing concentration of antibody and surface CEA, and was lost by using the parent
murine IgG1 PR1A3. Killing was also blocked by antibody to the Fc-gIIIA receptor. Purified human NK cells were effective at much
lower effector:target ratios than unfractionated PBMCs, indicating that NK cells were the main mediators of hPR1A3-based CEA-
specific killing. The results support the development of hPR1A3 for therapy of colorectal cancer.
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There has been a recent resurgence of interest in the use of
monoclonal antibodies for the treatment of cancer, mostly in the
setting of metastatic disease, and already a number of antibodies
have been licensed for use (for review see Reichert and Valge-
Archer, 2007). Antibody therapy directed at cell surface compo-
nents, in particular cell membrane receptors, has the potential to
exploit the specificity and sensitivity of the immune system’s
ability to recognise cell membrane receptors, and so to achieve
selective therapeutic effects without the toxicity of standard
chemotherapy. As a result antibody therapy has become a useful
adjunct to the treatment of cancer. This comes despite poor initial
results with murine antibodies (Clynes, 2006). The development of
chimeric and humanised antibodies has led to the development of
a second generation of antibodies that hardly, if at all, stimulate
the development of human anti-mouse antibodies, and which are
potent activators of the immune system (Carter, 2006). Currently,
about 19 antibodies are licensed for clinical use, 11 of which are for
the treatment of cancer (Reichert and Valge-Archer, 2007). There
are, it is estimated, at least a further 150 antibodies in
development. Antibody use has had a major impact on the
treatment of haematological malignancies with excellent response
rates seen using rituximab (anti-CD20) in follicular and B cell non-
Hodgkin’s Lymphoma (Olszewski and Grossbard, 2004). Their
impact in solid tumours has, however, been less dramatic. A major
reason for this must be the limited penetration of antibodies, being
large glycoproteins, into the tumour. Three antibodies have been
licensed by the US FDA for use in advanced colorectal cancer.
These include antibodies against EGFR (cetuximab) and VEGF
(bevacizumab). A problem with the former is the presence of EGFR
on cells of a variety of normal tissues leading to a degree of
nonspecificity with respect to cancer. The EGFR antibody also
appears to be effective in only a proportion of cancer patients. It is
therefore important to look for other potential antigens to use as
targets to broaden the number of patients for which antibody-
based immunotherapy may be effective.
Carcinoembryonic antigen (CEA or CEACAM5) was first
recognised as a potential human tumour-specific antigen in the
1960s (Gold and Freedman, 1965; Berinstein, 2002). CEA has
characteristics that make it a useful target for antibody therapy in
colorectal cancer (CRC). It is overexpressed in the vast majority of
CRCs (Chan and Stanners, 2007). More importantly, however it is
always aberrantly expressed in CRC. While the CEA expressed on
normal colonic epithelium is inaccessible to IgG antibody, being
found only on the luminal surface of the cell, this expression
pattern changes in the neoplastic cell so that CEA is additionally
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sexpressed on the basal and lateral membranes (Hammarstrom,
1999) making it accessible to blood-borne antibody. Although a
member of the Ig superfamily, CEA is linked to the cell membrane
by a glycophosphatidylinositol (GPI) anchor (Thompson et al,
1991) and thus has no direct intracellular signaling motif. The
functional significance, if any, of its overexpression in colorectal
cancer remains unclear. The biggest disadvantage of CEA as a
target is that it is readily cleaved from the cell surface and so shed
into the blood stream from tumours, either directly or via the
lymphatics, which is why the level of serum CEA has been used in
the clinic as a marker for screening and recurrence, especially of
colorectal cancer (Chau et al, 2004). Serum CEA binds to most of
the currently used anti-CEA antibodies hindering them from
reaching their target and so largely mitigating against any potential
clinical effect. This is, however, not the case for the murine
antibody, mPR1A3 developed in the ICRF laboratories in London
by Richman and Bodmer (1987).
PR1A3 was shown to target the B3 domain and GPI anchor of
the CEA molecule by Durbin et al, 1994 (see Figure 1), and was
subsequently humanised by Stewart et al, 1999. Murine PR1A3 has
been shown to react poorly with soluble CEA, which lacks the GPI
anchor, and has been used in immunoscintigraphy for the
detection of colorectal tumours with a high degree of specificity
(Granowska et al, 1989). In contrast to EGFR and VEGF, there are
so far no unconjugated, or ‘naked’ antibodies to CEA being used
for the treatment of colorectal cancer. The anti-CEA antibodies
that are currently used in pilot trials, are administered as
radioconjugates (Wong et al, 2004; Liersch et al, 2007).
Strong evidence for the suggestion that the antitumour effects of
antibodies are mediated mainly by ADCC (antibody-dependent
cellular cytotoxicity) comes from mouse knockout studies which
showed that antibody antitumour effects were largely absent in
mice lacking the appropriate Fc receptor (Clynes et al, 1998). In
humans, natural killer (NK) cells that express the CD16
Fcgreceptor are thought to be the main cell type that could
mediate ADCC of tumours (Arnould et al, 2006). Several
criteria, therefore, need to be fulfilled before an antibody can be
considered for therapy (Reichert and Valge-Archer, 2007).
Humanised antibodies are more potent activators of the human
immune system than their murine equivalents. Internalisation of
antibody-antigen complexes, leading to a loss of antibody
complexes available for binding to Fc receptor-bearing cells, will
diminish the effectiveness of antibody-based killing.
This study has three aims. First to analyse the ability of
humanised hPR1A3 to react with a panel of colorectal cancer cell
lines expressing high and low levels of CEA. Second to explore the
use of hPR1A3 in an in vitro cytotoxicity model and to compare
human PBMC with partially purified NK cells as effectors for
ADCC. The third aim was to investigate whether soluble CEA
inhibited the ADCC activity of hPR1A3 in vitro.
MATERIALS AND METHODS
Cell lines
The gastric carcinoma cell line MKN45 (Motoyama et al, 1979) was
obtained from Cell Services LIF, Cancer Research UK. All other cell
lines were colorectal cell lines:
HCT-116 (Brattain et al, 1981) and SKCO-1 (Fogh, 1975) were
originally obtained from ATCC; GP5d (Solic et al, 1995) and
HT55(Watkins and Sanger, 1977) were obtained from ECACC;
LS174T (Tom et al, 1976) was obtained from BH Tom, NW
University Med Centre, Chicago, Ill, USA, PC/JW (Paraskeva et al,
1984) was obtained from C. Paraskeva, Directors Lab, CRUK,
London and C70 (Browning et al, 1993) was established in the
Cancer and Immunogenetics Laboratory.
All cell lines were maintained in culture in Dulbecco’s modified
Eagle’s (E4) medium with 1% L-glutamine, 10% fetal calf serum
(FCS) and 1% penicillin/streptomycin. They were incubated at
371C in a humidified 10% CO2 environment. For the chromium-
release and EuTDA assays the cells were suspended in 2% RPMI-
1640 medium with 1% glutamine and 10% FCS.
Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated either
from fresh whole blood from healthy laboratory volunteers, having
taken informed consent, or from leucodepletion filters obtained
from single donors following blood donation (Courtesy of Cristina
Navarrete, Colindale National Blood Service, London, UK). White
cells were eluted from the filter using 5mM ethylenediaminete-
traacetic acid. Fresh whole blood was mixed with an equal
volume of an RPMI-1640/citrate solution (40ml 3.3% sodium
citrate, 2ml 5mM 2-mercaptoethanol, 200ml RPMI-1640þhepes)
as an anticoagulant.
Both sources of PBMC were then processed in an identical
fashion. Following Ficoll/hypaque density centrifugation, the
PBMC layer was withdrawn from the interface and washed once
with RPMI-1640 to remove excess Ficoll, spinning at 800g (Boyum,
1968) and then a second time, spinning at 200g for 10min to
remove platelets. The resulting PBMCs were resuspended in RPMI-
1640/10% FCS/1% glutamine (complete RPMI-1640), kept at room
temperature and used within 12h of preparation.
Antibodies
PR1A3 The original is a murine IgG1k monoclonal antibody to
CEA (Richman and Bodmer, 1987) that was later humanised
(Stewart et al, 1999). Both murine (mPR1A3) and humanised
(hPR1A3) antibodies were obtained from the Biotherapeutics
Development Unit, Clare Hall, Cancer Research UK, London, UK.
Anti-CD16 Two different clones of this antibody were used:
MEM154 (Biovendor Laboratory Medicine Inc.) and 3G8 (BD
Biosciences, Pharmingen, USA). Both are murine monoclonal
IgG1k antibodies against the human FcgIIIA receptor (CD16A;
FCGR3A). F(ab’)2 derived from the 3G8 clone was obtained from
Ancell Corp, Bayport, MN, USA.
NH2
N domain
A1
B1
A2
B2
A3
B3
Extracellular
PR1A3
Glycosylation site
Disulphide bridge between cysteines
Cell membrane
Intracellular
Figure 1 Schematic diagram showing the binding site of PR1A3 on CEA.
The antibody binds at a site involving parts of the GPI anchor and the B3
domain of CEA. Access to the epitope appears to be blocked when CEA is
released from the cell.
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sAnti-prostate specific membrane antigen Murine monoclonal
antibody 107-1A4 to PSMA was kindly provided by Robert
Vessella (Univ Washington, USA).
Polyclonal rabbit anti-mouse antibody This was obtained from
DAKO A/S, Denmark, and was diluted to 1:100 in RPMI-1640/1%
FCS.
Anti-b-galactosidase antibody clone 4C7 (Durbin and Bodmer,
1987), was obtained from the Monoclonal Antibody Service, Clare
Hall, Cancer Research UK, London, UK, and used at a final
concentration of 0.4mgml
 1 in RPMI-1640/1% FCS.
AUA-1 This was obtained from the Monoclonal Antibody
Service, Clare Hall, Cancer Research UK, London, UK (Epenetos
et al, 1982). It has been shown to be an anti-EpCam antibody
(Spurr et al, 1986).
FITC-conjugated murine anti-human IgG and FITC-conjugated
rabbit anti-mouse IgG These were obtained from Sigma-Aldrich,
Poole, UK.
CD3-FITC, CD16-PE, CD56-APC, IgG1-FITC (isotype control), IgG1-
PE (isotype control) and IgG1-APC (isotype control) These were
obtained from BD Biosciences Pharmingen, Oxford, UK.
Chromium-release cytotoxicity assay
Peripheral blood mononuclear cells were prepared as above
and suspended at a concentration of 1 10
7ml
 1 in RPMI-1640
supplemented with 10% FCS and 1% glutamine (complete
medium). 2 10
6 target cells were centrifuged at 400g for 5min,
decanted and labelled by resuspending the pellet in 0.1ml of
7.4MBq of Na2
51CrO4. This cell suspension was incubated at 371C
for 60–100min depending on the optimal labelling time for the
particular cell line. Optimal labelling time had previously been
determined by choosing the labelling time with the highest
maximal lysis:background radioactivity ratio. The cells were then
washed twice with RPMI-1640 and suspended in complete RPMI-
1640 at a concentration of 1 10
5 cells per ml. Target cells (100ml
(1 10
4)) and PBMCs (100ml( 1  10
6)) were added to micro-
centrifuge tubes to give an effector: target ratio of 100:1. Various
antibody concentrations (20ml) were then added to the relevant
tubes. Triton (120ml of 5%) was added to 100ml of target cells to
obtain maximum release values. All tubes were made up to the
same volume using complete RPMI-1640. The tubes were spun at
200g for 2min and the pellet of combined target and effector cells
was incubated at 371C for 4h in the presence of antibody. The
tubes were then spun at 200g for 5min and 35ml of the
supernatant added to 100ul Optiphase Supermix (Perkin Elmer,
Boston, MA, USA) in a 96-well plate. The
51Cr concentration in
each well was then determined using a Microbeta plate reader.
Fluorescence-based EuTDA cytotoxicity assay
Five microlitres of BATDA (Blomberg et al, 1996) (Perkin Elmer,
Boston, MA, USA) were added to 2 10
6 target cells suspended in
complete RPMI-1640 and incubated for 10–25min at 371C
depending on the optimal labeling time for the particular cell
line, determined as described for the
51Cr-release assays. The
relative concentrations of target cells and antibody in the
microcentrifuge tubes were similar to those used for the
51Cr
release assay. However, varying effector:target cell ratios were used
for the fluorescence-based assay. After spinning at 200g for 2min
the tubes were incubated at 371C for 2h and then spun again at
200g for 5min. A total of 20ml of the resulting supernatant
was added to 200ml of Europium in black 96-well plates and
the resulting fluorescence was then read in a time-resolved
fluorometer using an excitation wavelength of 340nm and an
emission wavelength of 615nm.
CEA ELISA assay
CEA levels were determined using a b-galactosidase/anti-
b-galactosidase ELISA (Durbin and Bodmer, 1987). Cells were
plated onto a poly-L-lysine coated 96-well Nunc-Immuno PolySorp
plate at a concentration of 2.5 10
4 cells per well. Murine PR1A3
was used as the CEA-detecting antibody with rabbit anti-mouse
antiserum as the secondary antibody. The GAG complex of
b-galactosidase with anti-b-galactosidase antibody was made by
dissolving b-galactosidase (E.coli b-galactosidase lyophilised
powder; Sigma-Aldrich, Poole, Dorset, UK) at a concentration of
500Uml
 1 in 100mM TRIS/100mM MgCl2/100mM 2-mercapto-
ethanol with 300mgml
 1 of 4C7 and incubating this complex
at 41C overnight. The complex so formed was then added at a
dilution of 1:750 in RPMI-1640/1% FCS. The GAG complex binds
to free antigen-binding sites on the rabbit anti-mouse IgG
antibody, which is already bound to the PR1A3 attached to the
CEA on the cells. The substrate 4-methylumbelliferyl-B-D-galacto-
side (Sigma-Aldrich, Poole, Dorset, UK) was first prepared at a
concentration of approximately 0.3mgml
 1 in a buffer of 1mM
MgCl2/100mM 2-mercaptoethanol . After stirring for 30min, the
solution was filtered to remove excess substrate. This substrate
solution was added to each well to start the reaction. After
incubation for 40min in the dark at room temperature,
fluorescence was measured using an excitation wavelength of
365nm and an emission wavelength of 445nm.
Flow cytometric analysis of CEA internalisation
The concentration of cells to be analysed was adjusted to
1 10
6ml
 1 and the cells washed once with phosphate-buffered
saline (PBSA) containing 2% FCS and then centrifuged at 400g for
five minutes. The resulting pellet was resuspended in cold PBSA
containing 2% FCS and incubated on ice with either 100mlo f
hPR1A3 at 20mgml
 1, 100ml of AUA-1 at 15mgml
 1 or a medium
control for 30min. The cells were next washed again, with PBSA
containing 2% FCS and incubated in a water bath at 371C for 0, 1, 2
or 3h. The cells were then incubated with a 1:50 dilution of FITC-
conjugated anti-human-IgG for hPR1A3 and a 1:100 dilution of
FITC-conjugated anti-murine IgG for AUA-1 on ice in the dark for
30min before being washed again and resuspended in PBSA
containing 2% FCS. The cells were then passed through a
fluorescence-activated cell sorting (FACS) Calibur flow cytometer
and the results analysed using CellQuest software.
NK cell enrichment
Fresh PBMC or eluted PBMC from leucodepletion filters were
enriched for NK cells using a Human NK Cell isolation kit
(Miltenyi Biotec) following the manufacturer’s instructions. This
involved adding the NK cell Biotin-Antibody cocktail (10ml per
10
7cells) which contained antibodies against T cells, B cells, stem
cells, dendritic cells, monocytes, granulocytes and erythroid cells.
Following incubation for 10min at 41C, the NK Cell magnetic
Microbead Cocktail was added. This was left for 15min at 41C and
the cells then washed with MACS buffer (PBSA/0.5% FCS/2mM
EDTA) and centrifuged. The cell pellet was resupended in 0.5mls
MACS buffer and then passed through an LS magnetic column to
remove cells that bound the antibodies in the cocktail. The cells
that passed through were then collected and suspended in
RPMI-1640 with and without IL-2 (Peprotech) at 10ngml
 1 and
incubated overnight at 371C. Aliquots pre and post sorting were
taken for FACS analysis with the antibodies CD3, CD56 and CD16
and the appropriate isotype controls. Thus, 1 10
6 cells were
suspended in 2ml of FACS buffer (PBSA/1%FCS/1% sodium azide)
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sand centrifuged. The supernatant was removed and the cells
resuspended in the residual buffer. The antibodies were then
added and left for 20min at 41C before washing and then fixing
with 300ml of 2% paraformaldehyde. The fixed cells were analysed
on a FACS Calibur flow cytometer. Gating of the lymphocyte
population in the forward versus side scatter plot revealed a purity
of at least 85% with respect to CD16 and CD56 binding. The
resulting NK cells were used in cytotoxicity assays with hPR1A3
against SKCO-1, which is known to express CEA.
Effect of soluble CEA on PR1A3-induced ADCC
Purified CEA, obtained from human liver colorectal metastasis,
was purchased from Chemicon and diluted in RPMI-1640 for use
in ADCC assays with NK cells (CD3 /CD56þ/CD16þ) that were
isolated from PBMC from a healthy volunteer. CEA was added to
achieve final concentrations of 2 and10mgml
 1. This concentra-
tion far exceeds any concentration that would be found in the
serum of a colorectal cancer patient. A level above 5ngml
 1 is
generally accepted as being raised. Patients with CEA levels above
15ngml
 1 have been found to have a worse prognosis (Wiratkapun
et al, 2001). The cytotoxicity assay was then carried out as
described above.
FACS analysis for competitive inhibition of hPR1A3
binding in the presence of soluble CEA
Soluble CEA at a final concentration of 10mgml
 1 was added to
hPR1A3 (final concentration 20mgml
 1). The mixture was
incubated in a 1.7ml eppendorf microtube for 45min at room
temperature. Humanised PR1A3 alone, at a concentration of
20mgml
 1, and medium alone were similarly incubated in a
microtube. Cells to be assayed with these various mixtures were
adjusted to a concentration of 1 10
6ml
 1 in RPMI-1640 complete
medium and washed with FACS buffer (PBSA/1%FCS/1% sodium
azide). The resulting pellet was resuspended in 10ml FACS buffer
and then incubated on ice with 100ml2 0 mgml
 1 mPR1A3,
hPR1A3/CEA (as prepared above) or medium control for 30min.
The cells were then washed twice with FACS buffer and incubated
on ice in the dark for 30min with a 1:50 dilution of FITC-
conjugated anti-human-IgG (for hPR1A3). The resulting labelled
cells were washed again with 2ml of FACS buffer and centrifuged
at 400g. The supernatant was removed completely and the cells
resuspended in 300ml of 2% paraformadehyde in PBSA. The
labelled cells were analysed using a FACS Calibur flow cytometer
as described before.
Data analysis
Percentage lysis of the cell lines in the cytotoxicity assays was
calculated as (experimental release background release)/(max-
imum release background release) 100. Percentage specific lysis
was calculated as (experimental release antibody independent
release)/(maximum release antibody independent release) 100.
The s.e.m. of multiple experiments was calculated using Graphpad
Prism software, San Diego, CA, USA. Standard normal distribution
tests were used to assess the significance of the differences found.
RESULTS
hPR1A3 binds to membrane-bound CEA and the
antibody–antigen complex is not internalised after 3h
Humanised PR1A3 showed specific binding to MKN45, a high
CEA-expressor. After three hours incubation of MKN45 at 371C
with hPR1A3, no change was observed in the amount of antibody
detected on the cell surface (Figure 2A). This is in contrast to the
results obtained in similar experiments using the anti-EpCAM
monoclonal antibody, AUA-1 (Figure 2B). In that case there is
already a significant reduction in the cell surface expression of
EpCAM after incubation for 1h at 371C indicating a fairly rapid
internalisation of the surface EpCAM/anti-EpCAM complex. These
data show that the CEA/anti-CEA(PR1A3) complex is not
significantly internalised even after 3h of incubation at 371C
(Figure 2).
hPR1A3 causes dose-dependent lysis of the high
CEA-expressing cell line, MKN45
MKN45 was used as a high CEA expressing cell line in cellular
cytotoxicity assays with
51Cr using different antibody concentra-
tions. In the absence of antibody, PBMCs effected a low but
significant level of spontaneous killing. The level of killing
increased with increasing concentrations of antibody, as would
be expected for ADCC (Figure 3).
Colorectal cancer cell lines express varying levels of CEA
The level of CEA expression on a subset of cell lines was assessed
using an ELISA assay with mPR1A3, and is given in Table 1 as
mean arbitrary fluorescence units (±s.d.).
These data correlate well with those obtained from FACS
analysis, RT–PCR and micro-array expression data (see
Supplementary Figure 1).
hPR1A3 treatment of MKN45 cells   AUA-1 treatment of MKN45 cells
4C 
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Figure 2 Time-course FACS analysis of hPR1A3 binding to CEA-expressing MKN45 cells. The cell line was labeled with primary antibody (PR1A3 or
AUA-1) at 41C and then incubated for varying times at 371C before addition of secondary antibody (FITC-conjugated anti-human IgG or anti-mouse IgG
respectively). (A) Analysis over time suggests that the CEA-PR1A3 complex is not internalised within 3h of binding to CEA. (B) Binding of the monoclonal
antibody AUA-1 to EpCAM on the surface of MKN45 cells leads to internalisation within one hour.
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sThe level of hPR1A3-mediated ADCC depends on the level
of CEA expression
HCT-116 was identified by FACS, ELISA and RT–PCR assays to
have no or at most a very low level of CEA expression. The killing
of the high expressing cell line MKN45 was therefore compared
with that of HCT-116 by hPR1A3 in the presence of human PBMC
using a EuTDA assay. While MKN45 was killed as expected, there
was no increase in lysis of HCT-116 above spontaneous killing
even with the highest concentration of antibody (Figure 4A). The
variation in hPR1A3-based ADCC lysis between cell lines
expressing different levels of CEA was assessed using PBMC and
a EuTDA assay. The results shown in Figure 4B indicate a good
correlation between CEA levels and the degree of hPR1A3-
mediated killing (Figure 4).
hPR1A3-mediated ADCC-based killings depends on the Fc
portion of the antibody
Since the murine IgG1 isoform does not associate strongly with the
human FcgIIIA receptor (Lubeck et al, 1985), mPR1A3 was
compared with hPR1A3 in killing assays on MKN45. The results
(Figure 5) show that murine PR1A3 did not kill above background,
in contrast to hPR1A3. This adds to the support for the
specificity of hPR1A3-based killing and suggests its dependence
on appropriate interaction with an Fcg receptor (Figure 5).
hPR1A3-dependent and spontaneous killing are both
inhibited by an anti-CD16 antibody, but only antibody-
dependent killing is inhibited by an F(ab’)2 of anti-CD16
Since the NK effector cells in PBMC, which are presumed to
mediate the majority of antibody-dependent killing, do so via the
CD16 (FcgIIIA) receptor (Titus et al, 1987; Lanier et al, 1988;
Moretta et al, 1989), the blocking effects on hPR1A3 killing of
MKN45 by anti-CD 16 and a F(ab’)2 of the same antibody were
investigated (Figure 6).
The results of blocking experiments with two different
concentrations of the reagents are shown in Figure 6. These data
show that anti CD16 completely blocked both spontaneous and
hPR1A3-induced killing. To ensure that this was a direct effect of
blocking the CD16 antibody receptor and not simply a conse-
quence of adding a second antibody which might compete for
Table 1 CEA expression determined by GAG-ELISA and given as mean
arbitrary fluorescence units ±s.d.
Cell line CEA expression (mean±s.d.)
SKCO-1 26804 (±1322)
PC-JW 20160 (±2124)
LS174T 19833 (±2618)
MKN45 19741 (±1769)
HT55 11954 (±1667)
HT29 4688 (±1185)
HCT-116 1995 (±1035)
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Figure 3 Humanised PR1A3-induced ADCC-mediated lysis is depen-
dent on the concentration of antibody. Cr-release ADCC assays were
done using MKN45 as CEA-expressing target cells and human PBMC as
effectors at a ratio of 100:1 effectors to targets. Columns represent mean
% lysis without antibody and with varying concentrations of hPR1A3. These
data shown are from the analysis of 14 separate experiments using MKN45
as the target cell and with triplicate wells for each condition in each
experiment. Error bars indicate standard error of the mean (s.e.m.).
*Indicates that significance of values is Po0.05 compared with samples
given no antibody.
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Figure 4 hPR1A3-mediated ADCC lysis of colorectal cancer cell lines
depends on their level of CEA expression. (A) Effect of increasing
concentrations of hPR1A3 on lysis of CEA-positive (MKN45) and -negative
(HCT-116) cell lines. Fluorescence-based ADCC assays were done using
human PBMCs as effector cells in a ratio of 100:1 with target cells.
Columns represent % lysis in the presence of both target and effector cells
with no, or with increasing concentrations of hPR1A3. *Po0.05 comparing
the cell lysis between MKN45 and HCT116. (B) Comparison of hPR1A3-
mediated ADCC based lysis in cell lines with different levels of CEA
expression (shown in parentheses) based on results in Table 1. The
EuTDA-based ADCC assay was done using human PBMCs as effector cells
at ratios of 100:1 with the various target cell lines. Nonspecific
spontaneous killing levels have been subtracted to reflect antibody-specific
lysis only.
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sFc-receptor sites, we added a non-specific antibody against
prostate membrane-specific antigen instead of anti-CD16 and this
did not block hPR1A3-mediated killing of MKN45.
In marked contrast to the blocking effects of whole CD16
antibody, the F(ab’)2 of the anti-CD16, which lacks the Fc-portion
of the antibody required for binding to the CD16 receptor on
effector cells, abolished only antibody-dependent killing but did
not affect the spontaneous lysis.
Purified NK cells are able to elicit ADCC with hPR1A3 at
much lower effector:target ratios than are unfractionated
PBMC
To establish that the major killing effect seen with hPR1A3 was
actually due to NK cells as conventionally defined, purified NK
cells were used in assays of hPR1A3 killing of the high CEA
expressing colorectal cell line, SKCO-1. NK cells were enriched
from PBMCs obtained from buffy coat (NBS) using the Human NK
Isolation kit, as described in Materials and Methods.
The extent of enrichment for NK cells is illustrated by the FACS
analysis shown in Figure 7A, using antibodies to CD16 and CD56.
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Figure 5 Comparison of humanised IgG1 and murine IgG1 isotypes of
PR1A3 in fluorescence-based ADCC assays using human PBMCs as
effectors and the MKN45 cell line. Effector:target ratios of 100:1 were used
in all assays. Columns represent mean % lysis from triplicate wells containing
both target and effector cells with no, or with increasing concentrations of
hPR1A3.
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Figure 6 Effect of whole or F(ab’)2 anti-CD16 on hPR1A3-mediated
lysis. Fluorescence-based ADCC assays were done using human PBMCs as
effector cells in a ratio of 100:1 with MKN45 target cells. Columns
represent mean % lysis from triplicate wells containing both target and
effector cells ±10mgml
 1 hPR1A3 ±second antibody as indicated. The
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Figure 7 (A) Demonstration of NK cell purification. NK cells were
purified from a single donor buffy coat sample (NBS) using the Human NK
isolation kit. FACS analysis was performed using CD56 and CD16
antibodies pre- and post-sorting to show the enrichment of NK cells, which
are both CD16- and CD56-positive. (B) Purified NK cells are much more
effective killers than unfractionated PBMC. PBMC and NK cells were
isolated from a single donor buffy coat (NBS). SKCO-1 was used as the
target in the presence of PBMC (W) or NK cells (B) with PR1A3
(50mgml
 1), or with no antibody (PBMC, ’; NK, X). The flouresence-
based EuTDA assay was used with effector:target ratios ranging from 10:1
to 50:1.
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sThe second panel clearly documents the extensive purification of
the CD16 and CD56 positive NK cells. The results of ADCC assays
with hPR1A3 using either these purified NK cells or unfractionated
PBMCs as effectors, and SKCO-1 as target cells, are shown in
Figure 7B. The difference in the effectiveness of killing by NK cells
as compared to unfractionated PBMCs is striking. Whereas in both
cases there is some spontaneous killing in the absence of antibody,
the NK cell antibody-specific killing is already very clear at the
lowest effector:target ratio of 10. There is, on the other hand,
barely detectable specific killing with the PMBCs even at a 50:1
effector: target ratio. Further data (see Supplementary Figure 2)
demonstrate that ADCC can occur in the presence of purified NK
cells even at effector: target ratios as low as 1:1. These results
provide strong support for the assumption that the hPR1A3
antibody-specific killing of CEA expressing human cell lines is
almost entirely due to the action of the human NK cells as effectors.
Neither hPR1A3 binding to, nor hPR1A3-mediated killing
of MKN45 are blocked by soluble CEA
The binding to the high expressing cell line SKCO-1 of hPR1A3
(20mgml
 1) on its own, or after preincubation with soluble CEA
(10mgml
 1) was investigated using a FACS analysis. The results,
illustrated in Figure 8A, show that there is no reduction in
reactivity of hPR1A3 with MKN45 after preincubation with CEA, as
compared to hPR1A3 alone. This corroborates for hPR1A3 the
earlier results obtained by Durbin et al, 1994 with mPR1A3, which
showed that soluble CEA does not block this antibody’s binding to
membrane bound CEA (Figure 8).
To show the same lack of effect of soluble CEA on hPR1A3-
specific killing, ADCC assays were carried out using fresh blood-
derived NK cells and SKCO-1 as target cells with hPR1A3 on its
own, or after preincubation with soluble CEA. The results,
illustrated in Figure 8B, clearly show that even preincubation with
10mgml
 1 of soluble CEA does not reduce the specific killing effect
of hPR1A3.
DISCUSSION
Our study has clearly shown that the humanised PR1A3 antibody
can be used for targeted killing of colorectal cancer lines that
express cell surface CEA. Both the direct binding of the antibody to
cells, and the extent of its ADCC activity against cells are
dependant on the level of surface expression of CEA. The fact, as
we have also shown, that CEA is not significantly internalised adds
another advantage to CEA as a target for naked antibody therapy.
This effectively increases the exposure times to Fcg receptor-
bearing cells by promoting attachment to antibody-coated target
cells. We have confirmed, as was shown previously for the murine
v e r s i o no fP R 1 A 3 ,t h a tt h eb i n d i n go fh P R 1 A 3t os u r f a c eb o u n dC E A
is not inhibited by soluble CEA, and in addition have shown that the
same is true for its ADCC activity. This property of PR1A3 accounts
for the low false-positive rate of lymph node detection in
immunoscintigraphy of colorectal cancers with PR1A3 in patients
(Granowska et al, 1989), given that it has been shown that soluble
CEA drains into lymphatics and so can become sequestrated into
regional lymph nodes in the absence of cancer cells (Kubo et al,1 9 9 2 ) .
Human NK cells are known to express CD16 (homologous to the
Fcg IV receptor in mice (Nimmerjahn and Ravetch, 2005)) and are
thought to play an important role in responses to antibody therapy
(Liljefors et al, 2003). We have shown that the ADCC activity of
hPR1A3 is dependent on its Fc domain. The evidence for this
comes both from the fact that mPR1A3, though it binds to surface
CEA on human cells, has no ADCC activity using human PBMC as
effectors, and that the ADCC activity of hPR1A3 is blocked both by
whole antibody to CD16 and by a CD16 F(ab’)2 fragment. The fact
that enrichment of human NK cells can elicit hPR1A3-dependent
ADCC at very low effector:target ratios when compared with
unfractionated PBMC, provides strong evidence that the ADCC
activity of hPR1A3 is actually mediated by human NK cells. That
the addition of the complete CD16 IgG, (but not the F(ab’)2
fragment) also abolishes antibody independent killing may be
explained either by antibody binding to CD16-bearing cells
100
80
60
%
 
o
f
 
m
a
x
40
20
0
100 101
FL1-H:: FL1-height
Isotype control
hPRIA3
hPRIA3+CEA
102 103
25
20
15
∗
∗ ∗
10
5
%
 
s
p
e
c
i
f
i
c
 
l
y
s
i
s
0
No antibody
CEA 10 g ml
–1
PR1A3 20 g ml
–1
PR1A3 20 g ml
–1 +CEA 2 g ml
–1
PR1A3 20 g ml
–1 +CEA 10 g ml
–1
–5
Figure 8 (A) Indirect staining and FACS analysis to study the effect of
addition of soluble CEA on humanised PR1A3 binding to SKCO-1. The left
histogram plot is the isotype control. The light grey curve represents the
histogram curve for hPR1A3 only (20mgml
 1) and the dark grey curve
represents the curve for hPR1A3 (20mgml
 1) that has been preincubated
with 10mgml
 1 of soluble CEA. (B) ADCC assay with hPR1A3 on its own,
or after preincubation with soluble CEA at final concentrations of 2 and
10mgml
 1, using purified NK cells (CD56þ/CD16þ/CD3 ) as effectors
and fluorescently labelled SKCO-1 cells as targets (effector:target ratio used
was 10:1). The controls used were no antibody and purified CEA with
target and effector cells only. *Indicates Po0.05 compared with the specific
lysis of target and effector cells alone.
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sreducing their mobility in the wells due to formation of clusters of
CD16þ cells or that killer cells may destroy CD16þ cells which
have bound the antibody.
The affinity of hPR1A3 for CEA appears to be relatively low as
reflected by the higher concentrations of PR1A3 needed to mediate
ADCC as compared to cetuximab (see Supplementary Figure 2).
However, this may be a potential advantage in the treatment of
solid tumours, since higher affinity antibodies may penetrate less
into tumours due to the majority of binding taking place at the
outer most part of a tumour (Adams et al, 2001). Intermediate
affinity antibodies may, thus, be predicted to have greater
penetration into solid tumours.
Much research is now directed at conjugating antibodies with
radiolabels or toxins. Although this has had some success in
experimental animal models, there remain significant problems in
the true in vivo situation, including especially the development of
an immune response against the toxins or enzymes linked to a
therapeutic antibody.
We suggest that the appropriateness of CEA as a therapeutic
target, together with our evaluation of antibody hPR1A3’s
mediated ADCC activity makes this antibody a very attractive
target for clinical development as a naked antibody. The main
challenge may be to enhance PR1A3’s ADCC activity, and this may
be achieved by glycoengineering its Fc hinge region (Umana et al,
1999), which has been shown to be a very effective method for
enhancing the effectiveness of antibody-mediated ADCC in vitro.
As previously discussed, only a small percentage of antibody
administered intravenously actually reaches the cells of a solid
tumour ((Allum et al, 1986; Delaloye et al, 1986; Epenetos et al,
1986; Colcher et al, 1987; Welt et al, 1990). While a small number
of antibody molecules reaching their tumour target may be
sufficient to elicit immune-based killing by ADCC, it seems
unlikely that such small amounts of antibody reaching a tumour
could have much effect in blocking function, since this would
require at least the majority of the antibody’s targets to be covered.
This emphasises the potential importance of immune mechanisms,
even for therapy with antibodies against targets such as EGFR and
ErbB with known functions, and so the importance of enhancing
ADCC for effective treatment, rather than improving the blocking
of function. The fact that CEA has no obvious function that might
be blocked by antibody does not mitigate against its use for naked
antibody-based therapy on the assumption that the primary
mechanism is immune and through ADCC. We believe that the
results we have presented here suggest that the naked anti-CEA
humanised antibody PR1A3, glycoengineered to increase its
efficacy in ADCC, may be an excellent candidate for therapy
of colorectal and other solid tumours that express significant levels
of CEA.
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